Bibliographical noteFunding Information:
Acknowledgments: we also acknowledge the BMT CTN 0201 and 0402 study investigators and participating centers. Support for these studies was provided to the Blood and Marrow Transplant Clinical Trials Network by grant #U10HL069294 from the National Heart, Lung and Blood Institute and the National Cancer Institute. The Department of the Navy, Office of Navy Research and the National Marrow Donor Program also provided support for the BMT CTN 0201 study. BMT CTN 0402 biospecimens were obtained from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC). Enrollment support was provided by DKMS Germany. Any views, opinions, findings, conclusions or recommendations expressed in this material are those of the author(s) and do not reflect the views or the official policy or position of the above-mentioned parties.
This manuscript was prepared using REDS II-LAPS Research Materials obtained from the NHLBI Biologic Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the REDS II-LAPS or the NHLBI. HN was a recipient of a grant from Takeda Science Foundation.
1Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA;2Division of Hematology, Saitama Medical Center, Jichi Medicial University, Saitama, Japan;3Division of Hematological Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA;4The Emmes Corporation, Rockville, MD, USA;5Division of Pediatrics BMT, Minneapolis, MN, USA and 6Center for International Blood and Marrow Transplant Research, Minneapolis Campus, Minneapolis, MN, USA Funding: this work was supported by National Institutes of Health, National Cancer Institute grants P01CA142106, CA183559, and CA183560, as well as by an ancillary laboratory study award provided by the Blood and Marrow Transplant Clinical Trials Network and the National Heart, Lung and Blood Institute and the National Cancer Institute (#U10HL069294).